Flowable Hemostats

Global Flowable Hemostats Market to Reach US$923.9 Million by 2030

The global market for Flowable Hemostats estimated at US$742.2 Million in the year 2024, is expected to reach US$923.9 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Bovine, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$616.5 Million by the end of the analysis period. Growth in the Porcine segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$202.2 Million While China is Forecast to Grow at 6.8% CAGR

The Flowable Hemostats market in the U.S. is estimated at US$202.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$184.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Flowable Hemostats Market – Key Trends & Drivers Summarized

Why Is the Demand for Flowable Hemostats Increasing in Surgical Procedures?

Flowable hemostats, used to control bleeding during surgical procedures, are gaining widespread adoption due to their efficacy in minimally invasive surgeries and trauma care. These gelatin- or collagen-based agents provide rapid hemostasis in complex surgical sites, making them essential in cardiovascular, orthopedic, and neurosurgical applications. The rising prevalence of chronic diseases requiring surgical intervention, coupled with the expansion of ambulatory surgical centers, is fueling demand for advanced hemostatic solutions. Additionally, as patient safety and surgical efficiency become top priorities, flowable hemostats are emerging as a preferred alternative to traditional gauze and sutures.

What Technological Advancements Are Improving Flowable Hemostats?

Innovations in bioengineered hemostatic agents, AI-powered surgical monitoring, and biodegradable formulations are transforming the flowable hemostat market. The development of thrombin-infused and fibrin-based hemostats is enhancing clotting speed and efficacy. AI-driven predictive analytics are assisting surgeons in assessing bleeding risks and optimizing hemostat application. Additionally, the rise of bioabsorbable and antimicrobial hemostatic agents is improving post-surgical outcomes by reducing infection risks. The integration of robotic-assisted surgery with automated hemostat delivery systems is further enhancing precision in surgical interventions. These technological advancements are making flowable hemostats more effective, safer, and adaptable to various surgical settings.

How Are Regulations and Market Trends Influencing Flowable Hemostats?

Stringent regulatory frameworks by the FDA, EMA, and WHO are shaping the development and commercialization of flowable hemostats, ensuring compliance with biocompatibility and safety standards. The increasing focus on cost-effective surgical care is driving the adoption of advanced hemostatic agents in outpatient and ambulatory settings. Additionally, the shift toward minimally invasive procedures is expanding the application of flowable hemostats in laparoscopic and robotic-assisted surgeries. The growing demand for single-use, pre-filled hemostatic syringes is further streamlining surgical workflows and reducing contamination risks. As regulatory requirements and surgical preferences evolve, flowable hemostats are becoming integral to modern healthcare practices.

What’s Driving the Future Growth of the Flowable Hemostats Market?

The future of flowable hemostats is being shaped by advancements in bioengineered clotting agents, AI-assisted surgical techniques, and the increasing adoption of personalized medicine. The development of nanotechnology-based hemostatic agents with targeted clotting mechanisms is expected to enhance precision in bleeding control. The integration of real-time AI-powered surgical analytics will further optimize hemostat application, improving patient outcomes. Additionally, the expansion of regenerative medicine and tissue engineering is expected to drive innovation in bioresorbable and stem cell-based hemostatic products. As surgical technology evolves, flowable hemostats will continue to play a vital role in improving surgical efficiency and patient safety.

SCOPE OF STUDY:

The report analyzes the Flowable Hemostats market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Origin (Bovine, Porcine); Application (General surgery, Cardiovascular surgery, Orthopedic surgery, Gynecological surgery, Neurosurgery, Reconstructive surgery, Other applications); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• 3-D Matrix Medical Technology
• Aegis Lifesciences
• B. Braun Melsungen AG
• Baxter International Inc.
• BD (Becton, Dickinson and Company)
• Biom`up
• C.R. Bard, Inc. (BD)
• Ethicon, Inc. (Johnson & Johnson)
• Gelita Medical GmbH
• Hemostasis LLC
• Integra LifeSciences
• Johnson & Johnson
• Marine Polymer Technologies, Inc.
• Medcura, Inc.
• Medtronic plc
• Pfizer Inc.
• Sanofi
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.